Drugs / SYD1875
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04202705 | Feb 2020 → Jun 2022 | cancer | Byondis B.V. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-08-11 | Byondis B.V. | Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875 byondis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYD1875 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04202705 ↗ |
| Route | Intravenous | “SYD1875 IV (in the vein) infusion every three weeks.” NCT04202705 ↗ |